T
0.010
0.00 (0.00%)
| Previous Close | 0.010 |
| Open | 0.010 |
| 52 Weeks Range |
| Profit Margin | -267.41% |
| Operating Margin (TTM) | -328.48% |
| Diluted EPS (TTM) | -30.42 |
| Quarterly Revenue Growth (YOY) | -61.80% |
| Total Debt/Equity (MRQ) | 420.52% |
| Current Ratio (MRQ) | 1.23 |
| Operating Cash Flow (TTM) | -22.87 M |
| Levered Free Cash Flow (TTM) | -10.21 M |
| Return on Assets (TTM) | -30.10% |
| Return on Equity (TTM) | -178.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Telesis Bio, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.1 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Relative Valuation | NA |
| Financial Health | -4.2 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.27 |
Select this tab to load the latest available analysis.
|
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents and BioXp biofoundry services. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 4.64% |
| % Held by Institutions | 30.00% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |